Ultomiris (ravulizumab-cwvz) — Medica

Generalized myasthenia gravis (gMG)

Initial criteria

age ≥ 18 years
Confirmed anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
Myasthenia Gravis Foundation of America classification II to IV
Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 6
Patient previously received or is currently receiving pyridostigmine OR had inadequate efficacy, a contraindication, or significant intolerance to pyridostigmine
Patient previously received or is currently receiving two different immunosuppressant therapies for ≥ 1 year OR had inadequate efficacy, a contraindication, or significant intolerance to two different immunosuppressant therapies (e.g., azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus, cyclophosphamide)
Evidence of unresolved symptoms of generalized myasthenia gravis

6 months